A carregar...
Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
Urothelial carcinoma is one of the most common cancers in the United States, yet outcomes are historically suboptimal. Since 2016, the approval of five programmed cell death 1 and programmed death-ligand 1 immune checkpoint inhibitors for locally advanced and metastatic urothelial carcinoma has led...
Na minha lista:
| Publicado no: | J Cancer Immunol (Wilmington) |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8276975/ https://ncbi.nlm.nih.gov/pubmed/34263255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.33696/cancerimmunol.3.047 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|